{
    "root": "30891c38-5d64-7df7-e063-6394a90ae762",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atazanavir",
    "value": "20250317",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "ATAZANAVIR SULFATE",
            "code": "4MT4VIE29P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31243"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        }
    ],
    "indications": {
        "text": "atazanavir capsules indicated combination antiretroviral agents treatment hiv-1 infection adults pediatric patients 6 years older weighing least 15 kg . limitations : \u2022 atazanavir recommended pediatric patients age 3 months due risk kernicterus [ ( 8.4 ) ] . \u2022 atazanavir ritonavir treatment-experienced patients guided number baseline primary protease inhibitor resistance substitutions [ microbiology ( 12.4 ) ] .",
        "doid_entities": [
            {
                "text": "kernicterus (DOID:2382)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2382"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "hiv-1 infection",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_324632"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 pretreatment testing : renal laboratory testing performed patients prior initiation atazanavir capsules continued treatment atazanavir capsules . hepatic testing performed patients underlying liver disease prior initiation atazanavir capsules continued treatment atazanavir capsules . ( 2.2 ) \u2022 treatment-naive adults : atazanavir capsules 300 mg ritonavir 100 mg daily food atazanavir 400 mg daily food . ( 2.3 ) \u2022 treatment-experienced adults : atazanavir capsules 300 mg ritonavir 100 mg daily food . ( 2.3 ) \u2022 pediatric patients : atazanavir capsule based body weight exceed adult dose must taken food . ( 2.4 ) \u2022 pregnancy : atazanavir capsules 300 mg ritonavir 100 mg daily food , dosing modifications concomitant medications . ( 2.6 ) \u2022 dosing modifications : may required concomitant therapy ( 2.3 , 2.4 , 2.6 ) , renal impairment ( 2.7 ) , hepatic impairment . ( 2.8 )",
        "doid_entities": [
            {
                "text": "liver disease (DOID:409)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_409"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "atazanavir capsules 150 mgare white pale yellow colored granular powder filled size `` 1 `` hard gelatin capsules green opaque cap imprinted `` h `` black color light green opaque body imprinted `` a6 `` black color . bottles 60 child-resistant closure ndc 31722-653-60 bottles 1000 child-resistant closure ndc 31722-653-10 carton 100 ( 10\u00d710 ) unit-dose capsules ndc 31722-653-31 150 mg atazanavir equivalent 170.854 mg atazanavir sulfate . atazanavir capsules 200 mgare white pale yellow colored granular powder filled size `` 0 `` hard gelatin capsules green opaque cap imprinted `` h `` black color light green opaque body imprinted `` a7 `` black color . bottles 60 child-resistant closure ndc 31722-654-60 bottles 1000 ct closure ndc 31722-654-10 carton 100 ( 10\u00d710 ) unit-dose capsules ndc 31722-654-31 200 mg atazanavir equivalent 227.805 mg atazanavir sulfate . atazanavir capsules 300 mgare white pale yellow colored granular powder filled size `` 00 `` hard gelatin capsules orange opaque cap imprinted `` h `` black color green opaque body imprinted `` a8 `` black color . bottles 30 child-resistant closure ndc 31722-655-30 bottles 500 child-resistant closure ndc 31722-655-05 carton 100 ( 10\u00d710 ) unit-dose capsules ndc 31722-655-31 300 mg atazanavir equivalent 341.708 mg atazanavir sulfate . keep capsules tightly closed container . store atazanavir capsules 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "atazanavir capsules contraindicated : \u2022 patients previously demonstrated clinically significant hypersensitivity ( eg , stevens- johnson syndrome , erythema multiforme , toxic skin eruptions ) components atazanavir capsules [ ( 5.2 ) ] . \u2022 coadministered drugs highly dependent cyp3a ugt1a1 clearance , elevated plasma concentrations interacting drugs associated serious and/or life-threatening events ( table 6 ) . \u2022 coadministered drugs strong inducers cyp3a due potential loss therapeutic effect development resistance . coadministration contraindicated , limited , following drugs listed table 6 : table 6 : drugs contraindicated atazanavir ( information table applies atazanavir without ritonavir , unless otherwise indicated ) class drugs within class contraindicated atazanavir capsules alpha 1-adrenoreceptor antagonist alfuzosin antiarrhythmics amiodarone ( ritonavir ) , quinidine ( ritonavir ) anticonvulsants carbamazepine , phenobarbital , phenytoin antimycobacterials rifampin antineoplastics apalutamide , encorafenib , irinotecan , ivosidenib antipsychotics lurasidone ( ritonavir ) , pimozide benzodiazepines orally administered midazolam , triazolam ergot derivatives dihydroergotamine , ergonovine , ergotamine , methylergonovine gi motility agent cisapride hepatitis c direct-acting antivirals elbasvir/grazoprevir ; glecaprevir/pibrentasvir herbal products st. john \u2019 wort ( hypericum perforatum ) lipid-modifying agents : lomitapide , lovastatin , simvastatin phosphodiesterase-5 ( pde-5 ) inhibitor sildenafil bwhen dosed revatio \u00aefor treatment pulmonary arterial hypertension protease inhibitors indinavir non-nucleoside reverse transcriptase inhibitors nevirapine , table 16 ( 7 ) parenterally administered midazolam . b , table 16 ( 7 ) sildenafil dosed viagra \u00aefor erectile dysfunction .",
    "indications_original": "Atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. \n    Limitations of Use: \n    \u2022\u00a0Atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus\n \n  [see Use in Specific Populations (\n  \n   8.4)]\n \n  .\u00a0 \n    \u2022\u00a0Use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions\n \n  [see Microbiology (\n  \n   12.4)]\n \n  .",
    "contraindications_original": "\u2022\u00a0Pretreatment testing: Renal laboratory testing should be performed in all patients prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. Hepatic testing should be performed in patients with underlying liver disease prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. ( 2.2 ) \u2022\u00a0Treatment-naive adults: Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food or atazanavir 400 mg once daily with food. ( 2.3 ) \u2022\u00a0Treatment-experienced adults: Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food. ( 2.3 ) \u2022\u00a0Pediatric patients: Atazanavir capsule dosage is based on body weight not to exceed the adult dose and must be taken with food. ( 2.4 ) \u2022\u00a0Pregnancy: Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food, with dosing modifications for some concomitant medications. ( 2.6 ) \u2022\u00a0Dosing modifications: may be required for concomitant therapy ( 2.3 , 2.4 , 2.6 ), renal impairment ( 2.7 ), and hepatic impairment. ( 2.8 )",
    "warningsAndPrecautions_original": "Atazanavir Capsules 150 mgare off white to pale yellow colored granular powder filled in size \"1\" hard gelatin capsules with green opaque cap imprinted with \"H\" in black color and light green opaque body imprinted with \"A6\" in black color. \n    Bottles of 60 with child-resistant closure\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 31722-653-60 \n    Bottles of 1000 with child-resistant closure\u00a0 \u00a0 \u00a0 NDC 31722-653-10 \n    Carton of 100 (10\u00d710) unit-dose capsules\u00a0 \u00a0 \u00a0 \u00a0NDC 31722-653-31 \n    150 mg atazanavir equivalent to 170.854 mg atazanavir sulfate. \n  \n                     Atazanavir Capsules 200 mgare off white to pale yellow colored granular powder filled in size \"0\" hard gelatin capsules with green opaque cap imprinted with \"H\" in black color and light green opaque body imprinted with \"A7'' in black color. \n    Bottles of 60 with child-resistant closure\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 31722-654-60 \n    Bottles of 1000 with CT closure\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 31722-654-10 \n    Carton of 100 (10\u00d710) unit-dose capsules\u00a0 \u00a0 \u00a0 \u00a0NDC 31722-654-31 \n    200 mg atazanavir equivalent to 227.805 mg atazanavir sulfate. \n  \n                     Atazanavir Capsules 300 mgare off white to pale yellow colored granular powder filled in size \"00\" hard gelatin capsules with orange opaque cap imprinted with \"H\" in black color and green opaque body imprinted with \"A8\" in black color. \n    Bottles of 30 with child-resistant closure\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 31722-655-30 \n    Bottles of 500 with child-resistant closure\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 31722-655-05 \n    Carton of 100 (10\u00d710) unit-dose capsules\u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 31722-655-31 \n    300 mg atazanavir equivalent to 341.708 mg atazanavir sulfate. \n    Keep capsules in a tightly closed container. \n    Store atazanavir capsules at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Atazanavir capsules are contraindicated: \n    \u2022\u00a0in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens- Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules\n \n  [see Warnings and Precautions (\n  \n   5.2)]\n \n  . \n    \u2022\u00a0when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events (see Table 6). \n    \u2022\u00a0when coadministered with drugs that strong inducers of CYP3A due to the potential for loss of therapeutic effect and development of resistance. \n    Coadministration is contraindicated with, but not limited to, the following drugs listed in Table 6: \n  \n                     Table 6:\u00a0Drugs Contraindicated with Atazanavir (Information in the table applies to atazanavir with or without ritonavir, unless otherwise indicated)\n                  \n                  \n                  \n                     \n                     \n                     \n                        \n                           \n                              Drug Class\n                              \n                           \n                           \n                              Drugs within class that are contraindicated with Atazanavir capsules\n                              \n                           \n                        \n                        \n                           Alpha 1-adrenoreceptor antagonist \n     \n                           \n                           Alfuzosin \n     \n                           \n                        \n                        \n                           Antiarrhythmics \n     \n                           \n                           Amiodarone (with ritonavir), quinidine (with ritonavir) \n     \n                           \n                        \n                        \n                           \u00a0Anticonvulsants \u00a0\u00a0 \u00a0 \u00a0\u00a0\n                           \u00a0Carbamazepine, phenobarbital, phenytoin\n                        \n                        \n                           Antimycobacterials \n     \n                           \n                           Rifampin \n     \n                           \n                        \n                        \n                           Antineoplastics \n     \n                           \n                           Apalutamide, encorafenib, irinotecan, ivosidenib \n     \n                           \n                        \n                        \n                           Antipsychotics \n     \n                           \n                           Lurasidone (with ritonavir), pimozide \n     \n                           \n                        \n                        \n                           Benzodiazepines \n     \n                           \n                           Orally administered midazolam\n    \n     a, triazolam \n     \n                           \n                        \n                        \n                           Ergot Derivatives \n     \n                           \n                           Dihydroergotamine,\u00a0ergonovine,\u00a0ergotamine,\u00a0 methylergonovine \n     \n                           \n                        \n                        \n                           GI Motility Agent \n     \n                           \n                           Cisapride \n     \n                           \n                        \n                        \n                           Hepatitis C Direct-Acting Antivirals \n     \n                           \n                           Elbasvir/grazoprevir; glecaprevir/pibrentasvir \n     \n                           \n                        \n                        \n                           Herbal Products \n     \n                           \n                           St. John\u2019s wort (\n    \n     Hypericum perforatum) \n     \n                           \n                        \n                        \n                           Lipid-Modifying Agents: \n     \n                           \n                           Lomitapide, lovastatin, simvastatin \n     \n                           \n                        \n                        \n                           Phosphodiesterase-5 (PDE-5) Inhibitor \n     \n                           \n                           Sildenafil\n    \n     bwhen dosed as REVATIO\n    \n     \u00aefor the treatment of pulmonary arterial hypertension \n     \n                           \n                        \n                        \n                           Protease Inhibitors\u00a0 \n     \n                           \n                           Indinavir \n     \n                           \n                        \n                        \n                           Non-nucleoside Reverse Transcriptase Inhibitors \n     \n                           \n                           Nevirapine \n     \n                           \n                        \n                     \n                  \n                  \n                     a\u00a0See\n \n  Drug Interactions, Table 16 (\n  \n   7)\n \n  for parenterally administered midazolam. \n  \n                     b\u00a0 See\n \n  Drug Interactions, Table 16 (\n  \n   7)\n \n  for sildenafil when dosed as VIAGRA\n \n  \u00aefor erectile dysfunction.",
    "drug": [
        {
            "name": "Atazanavir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37924"
        }
    ]
}